Hormonal
Dietary capsaicin (0.01%) prevents diet-induced obesity in wild-type mice by activating TRPV1 channels, which triggers intracellular calcium elevation and subsequent phosphorylation of CaMKII and AMPK, leading to SIRT-1 activation, PPARγ deacetylation, and the browning of white adipose tissue (WAT).
This research suggests that adding a small amount of capsaicin (0.01% of diet) to a high-fat diet can prevent obesity in mice by turning white fat into energy-burning brown fat. This happens through a specific chain reaction starting with TRPV1 activation. For humans, this implies that spicy foods might support metabolic health, but the dose required in the study is specific and the sensory experience is intense. It does not mean you can eat unlimited fat; it means capsaicin may help mitigate some effects of a poor diet by increasing energy expenditure.
Capsaicin triggered browning of WAT by promoting sirtuin-1 expression and activity via TRPV1 channel-dependent elevation of intracellular Ca2+ and phosphorylation of Ca2+/calmodulin-activated protein kinase II and AMP-activated kinase.
Why this rating
The study uses robust animal models (WT vs. TRPV1 knockout) and multiple assays (CLAMS, Western blot, PCR), but results are limited to mice and do not establish human efficacy or safety.
Source
Capsaicin induces browning of white adipose tissue and counters obesity by activating TRPV1 channel‐dependent mechanisms
Padmamalini Baskaran et al. · British Journal of Pharmacology · 2016
DOI 10.1111/bph.13514
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →